Home Cart 0 Sign in  
X

[ CAS No. 1221171-95-4 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 1221171-95-4
Chemical Structure| 1221171-95-4
Chemical Structure| 1221171-95-4
Structure of 1221171-95-4 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 1221171-95-4 ]

Related Doc. of [ 1221171-95-4 ]

Alternatived Products of [ 1221171-95-4 ]

Product Details of [ 1221171-95-4 ]

CAS No. :1221171-95-4 MDL No. :MFCD22571777
Formula : C6H2ClF3INO Boiling Point : -
Linear Structure Formula :- InChI Key :AFPPAOOKEWWCBK-UHFFFAOYSA-N
M.W : 323.44 Pubchem ID :49871100
Synonyms :

Calculated chemistry of [ 1221171-95-4 ]

Physicochemical Properties

Num. heavy atoms : 13
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.17
Num. rotatable bonds : 2
Num. H-bond acceptors : 5.0
Num. H-bond donors : 0.0
Molar Refractivity : 48.65
TPSA : 22.12 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -5.45 cm/s

Lipophilicity

Log Po/w (iLOGP) : 2.3
Log Po/w (XLOGP3) : 3.98
Log Po/w (WLOGP) : 4.5
Log Po/w (MLOGP) : 2.53
Log Po/w (SILICOS-IT) : 3.59
Consensus Log Po/w : 3.38

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -4.56
Solubility : 0.00886 mg/ml ; 0.0000274 mol/l
Class : Moderately soluble
Log S (Ali) : -4.15
Solubility : 0.0231 mg/ml ; 0.0000715 mol/l
Class : Moderately soluble
Log S (SILICOS-IT) : -4.2
Solubility : 0.0206 mg/ml ; 0.0000638 mol/l
Class : Moderately soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 2.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 2.4

Safety of [ 1221171-95-4 ]

Signal Word:Warning Class:
Precautionary Statements:P261-P264-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P362-P403+P233-P501 UN#:
Hazard Statements:H315-H319-H335 Packing Group:
GHS Pictogram:

Application In Synthesis of [ 1221171-95-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 1221171-95-4 ]
  • Downstream synthetic route of [ 1221171-95-4 ]

[ 1221171-95-4 ] Synthesis Path-Upstream   1~1

  • 1
  • [ 1221171-95-4 ]
  • [ 1221171-96-5 ]
YieldReaction ConditionsOperation in experiment
80%
Stage #1: With n-butyllithium; diisopropylamine In tetrahydrofuran; hexane at -78℃;
Stage #2: With hydrogenchloride In tetrahydrofuran; hexane; water
2-ChIoro-4-iodo-6-trifluoromethoxy pyridine (42); At 0 0C, diisopropylamine (1.4 g, 1.9 mL, 13.6 mmol, 1.1 eq) was added dropwise to a solution of butyllithium (1.56 M in hexane, 9.0 mL, 13.6 mmol, 1.1 eq) in THF (20 mL). At -78 0C, a solution of 2-chloro-5-iodo-6-trifluoromethoxypyridine (41, 4.0 g, 12.4 mmol, 1 eq) in THF (10 mL) was added dropwise and the reaction mixture was stirred for 1 h at this temperature. It was then neutralized with a solution of hydrochloric acid (2N, 10 mL), treated with a saturated aqueous solution sodium hydrogencarbonate (30 mL) and extracted with diethylether (3 x 20 mL). The combined organic layers were dried over sodium sulfate before being evaporated. The crude dark oil was distilled under vacuum (b.p. 104-107 0C / 16 mbar) to afford pure 2-chloro-4-iodo-6- trifluoromethoxypyridine (42, 3.2 g, 10.9 mmol, 80percent) as a colorless oil; 1H NMR(CDCl3, 300 MHz): δ = 7.66 (d, J= 1.0 Hz, 1 H), 7.34 (d, J= 1.0 Hz, 1 H). - 19F NMR (CDCl3, 282 MHz): δ = -57.1 - 13C NMR (CDCl3, 75 MHz): δ = 155.1, 149.4, 130.7, 120.3, 119.1 (q, J= 262 Hz), 108.3.
Reference: [1] Patent: WO2010/40461, 2010, A1, . Location in patent: Page/Page column 44
[2] European Journal of Organic Chemistry, 2010, # 31, p. 6043 - 6066
Same Skeleton Products
Historical Records